Skip to content
Get alerts
GovInfoNow
Lower risk Drug recall · FDA · Published July 29, 2025

Pfizer Recalls Levoxyl 50 mcg Tablets: Subpotent Drug Risk

Pfizer recalls Levoxyl 50 mcg tablets due to subpotent drug content. This may not provide proper thyroid hormone levels. Affected lots: 24C11, expiring 2/28/2026.

Plain-English summary generated from official FDA data by GovInfoNow · Published by Carlos Caban · How we make summaries

🇺🇸 FDA recall #D-0575-2025DrugPfizer ›
Take action

Contact the company

Recalling firmPfizer66 Hudson Blvd · Manhattan, NY 10001
✎ GovInfoNow plain-language explainer

Pfizer is recalling Levoxyl 50 mcg thyroid medication tablets because they may not contain enough active ingredient. This could lead to improper thyroid hormone levels if taken without replacement. Read more at govinfonow.com/recall/31953-pfizer-recalls-levoxyl-50-mcg-tablets-subpotent-drug-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/31953-pfizer-recalls-levoxyl-50-mcg-tablets-subpotent-drug-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0575-2025

Cite this page

“Pfizer Recalls Levoxyl 50 mcg Tablets: Subpotent Drug Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31953-pfizer-recalls-levoxyl-50-mcg-tablets-subpotent-drug-risk. Based on FDA recall #D-0575-2025 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0575-2025%22&limit=1).

The FDA announced on July 29, 2025, that Pfizer has voluntarily recalled Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, due to subpotent drug risks. Owners should contact Pfizer for a remedy.

How to tell if you have it

  • Brand: Pfizer
  • Product: Levoxyl (levothyroxine sodium tablets, USP)
  • Strength/Format: 50 mcg, 100-count bottle
  • NDC: 60793-851-01
  • Lot #: 24C11
  • Expiration Date: Exp 2/28/2026
  • Distribution: Within U.S.

The hazard

The recall is due to the drug being subpotent. The FDA classified this as a Class II recall.

Context

GovInfoNow's records show Pfizer has issued three other recalls since June 28, 2018, including a lack of sterility risk in September 2026 and glass particulate matter hazards in December 2023. Other recent recalls of similar products include Major Pharmaceuticals Levothyroxine Tablets Recall (July 13, 2026), Macleods Levothyroxine Tablets Recall (Feb. 26, 2026), and Accord Healthcare Levothyroxine Tablets Recall (Aug. 6, 2026).

How to tell if you have this one

Check for the lot number 24C11 on the bottle label. The product is a 100-count bottle of Levoxyl 50 mcg tablets, distributed by Pfizer and made in Austria, expiring 2/28/2026.

  • Brand
    Pfizer
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Look for the lot number 24C11 on the bottle label to confirm if it's affected.

How this recall unfolded

Recall timeline

FDA published this recall 22 days after the firm started it.

1. Firm started the recall: Jul 29, 202512. FDA classified it Class II: Aug 8, 202523. Published in FDA’s Enforcement Report: Aug 20, 202532025
  1. Firm started the recall
  2. FDA classified it Class II
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Major Pharmaceuticals Levothyroxine Tablets Recall: Subpotent Drug Risk
Major PharmaceuticalsMacleods Levothyroxine Tablets Recall: Subpotent Drug Risk
Macleods PharmaAccord Healthcare recalls Levothyroxine tablets with subpotent drug risk
Accord HealthcareAccord Healthcare Levothyroxine Tablets Recall: Subpotent Drug Risk
Accord HealthcareAmerican Health Packaging Recalls Metoclopramide Tablets Due to Foreign Drug Presence
American Health Packaging

Latest drug recalls

Teva Pharmaceuticals USA, Inc recalls Metoclopramide Tablets, USP, 5 mg, [100 or 500] Tablets per bottle, Rx Only, Manufactured for: Teva Pharmaceuticals,
Teva Pharmaceuticals · September 29, 2026Preferred Pharmaceuticals, Inc. recalls Lidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx only, Mfg: Taro Pharmaceuticals U.S.A.,
Preferred Pharmaceuticals · September 28, 2026SUN PHARMACEUTICAL INDUSTRIES INC recalls Tretinoin Cream USP, 0.05%, 45 g tube, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Taro
Northstar Rx · September 25, 2026Apothecary Pharma LLC recalls Tirzepatide Injection, 18mg/mL, 4 mL Sterile Multi-Dose Vial, Rx only, Apothecary Pharma, LLC, 1913 Evans Road, Cary,
Apothecary Pharma · September 24, 2026Apotex Corp. recalls Paroxetine Extended-Release Tablets, 37.5mg, 30-count bottle, Rx only, Manufactured by: Apotex Inc., Toronto, Ontario,
Apotex · September 23, 2026Cipla USA, Inc. recalls Fosfomycin Tromethamine Granules for Oral Solution, (Equivalent to 3 Grams of Fosfomycin), 1 Single-Dose Sachet, Rx
Cipla USA · September 18, 2026

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0575-2025 (July 29, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0575-2025 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA